1. 1812 Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival. Retrospective analyses of the STO3 randomizedtrial. (September 2015) Authors: Lindström, L.S.; Yau, C.; Czene, K.; Thompson, C.K.; Van't Veer, L.J.; Nordenskjöld, B.; Stål, O.; Fornander, T.; Benz, C.C.; Borowsky, A.D.; Esserman, L.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗